Abstract-Ascorbic acid appears to have vasodilatory properties, but the underlying mechanisms are not well understood.
A scorbic acid (vitamin C) is the main water-soluble antioxidant in human plasma. 1 It improves endotheliumdependent vasodilation in patients with non-insulindependent diabetes, 2 heart failure, 3 and hypertension 4 or in long-term smokers. 5 Although ascorbic acid has been suggested to act by enhancing the effects of liberated endothelial vasodilators, the mechanism of its vascular effects is not well characterized.
Ascorbic acid scavenges reactive oxygen species including superoxide, 6 protects isolated LDL against oxidative modification, 7 and plays an important role in the regulation of intracellular redox state. 8 It prevents nitrate tolerance in coronary arteries in vivo and augments the production of platelet cGMP in vitro. 9 In addition, ascorbic acid maintains coronary vasodilation and production of cGMP in platelets during prolonged infusion of glyceryl trinitrate in patients with congestive heart failure, providing further evidence that it impedes development of nitrate tolerance. 10 In these studies, it was not investigated whether ascorbic acid produces any direct effects in veins despite the fact that these vessels are the primary target for nitrate-induced vasodilation. Moreover, venodilatory effects of ascorbic acid should be of great clinical importance because they are expected to improve the efficacy of nitrates and prevent nitrate tolerance.
Oral doses of ascorbic acid as low as 500 mg per day for 30 days 11 or 6 months 12 slightly lower systolic and mean arterial blood pressure. Because direct vasodilation by ascorbic acid is not present in the brachial artery, 13 this effect could be caused by dilation of the venous vasculature. Venodilation decreases venous blood return to the heart, which determines cardiac output. 14, 15 Simultaneous determinations of cardiac function and venous return curves have shown that maximal reflex change in venous capacitance could alter cardiac output up to 40%. 16 Therefore, the decrease in systolic blood pressure (which mirrors a fall in stroke volume) found in the above-mentioned studies could be attributed to venodilation.
In previous investigations of drug-induced dilation of the preconstricted human hand veins, in which we have used ascorbic acid as a model antioxidant, we observed substantial vasodilation. This effect was present at local concentrations (up to 10 mmol/L) that did not dilate the brachial artery. 2, 4, [17] [18] [19] Here we studied the direct venodilatory effects of ascorbic acid in the same model to elucidate the underlying mechanism of action by using various pharmacological tools. Putative endothelium-dependent effects were investigated by blocking nitric oxide (NO) synthase with N G -monomethyl-Larginine (L-NMMA) and cyclooxygenase with acetylsalicylic acid (ASA). In addition, we tested whether ascorbic acid affects intracellular calcium concentrations of cultured endothelial cells. The contribution of endothelium-independent processes to ascorbic acid-induced venodilation was examined with methylene blue to inhibit cGMP generation, with quinidine for unselective block of potassium channels, and with glibenclamide for selective block of ATP-dependent potassium channels.
Methods Subjects
Twenty-three healthy, male nonsmokers, 20 to 30 years old (meanϮSD; 23Ϯ3 years) participated in 1 or more study days. Their body weights ranged from 68 to 96 kg (78Ϯ8 kg). Exclusion criteria included a history of any significant disease, drug abuse, alcoholism, or chronic use of any medication. Subjects were allowed a light breakfast on study days but were asked to refrain from caffeinecontaining beverages for Ն12 hours before the study. The study was approved by the Human Research Committee of the Medical Faculty of the University of Technology, Dresden. All subjects gave written informed consent.
Drugs
All drugs were diluted in normal saline solution. The following drugs were used: ascorbic acid (Jenapharm), phenylephrine hydrochloride (American Regent Laboratories), prostaglandin (PG)F 2␣ (Upjohn), L-NMMA (Clinalfa), methylene blue (Neopharma), and quinidine gluconate (Eli Lilly and Co). ASA (Roche Nicholas Deutschland) was given orally. Glibenclamide for intravenous use (HB 419, batch 34) was a generous gift of Hoechst Marion Roussel, Bad Soden, Germany.
Because ascorbic acid could decrease the local pH value in the vein, particularly considering the lower flow velocity of the venous system, we measured final pH values of solutions containing different amounts of ascorbic acid with additional quantities of PGF 2␣ or phenylephrine. The pH values were in the same range as NaCl solution used as solvent (data not shown). Assuming a venous blood flow of 3 mL/min and an infusion rate of 0.3 mL, the final intravenous pH value obtained after blending of any infused solution with the venous blood is calculated to be 7.2 to 7.3, that is, within the physiological range.
Dorsal Hand Vein Technique
The diameter of a dorsal hand vein, distended by inflation of an upper arm cuff to 40 mm Hg, was measured by the method of Aellig, 20 modified as previously described. 21, 22 
Direct Effects of Ascorbic Acid on Dorsal Hand Vein Distensibility
After Ϸ80% preconstriction of the basal vein size (see Table) was obtained with phenylephrine (47 to 1500 ng/min), complete doseresponse curves to ascorbic acid (5 to 6000 g/min) were constructed in 9 subjects. On separate study days, 6 subjects received ascorbic acid after 80% preconstriction of the basal vein size was obtained with PGF 2␣ (a vasoconstrictor independent of adrenergic mechanisms 23 ; dose range, 59 to 7500 ng/min).
Five additional study protocols with similar basic design have been performed to explore the underlying mechanism of ascorbic acid-induced venodilation. Three sets of experiments, performed on separate study days, used phenylephrine as preconstrictor. To explore the involvement of cyclooxygenase products in venodilation, oral aspirin (1 g) was given 2 hours before a dose-response curve to ascorbic acid was constructed in 5 subjects. Five subjects received increasing doses of ascorbic acid in the presence of L-NMMA (6.3 mol/min) on a separate study day to evaluate the contribution of NO. To determine whether generation of cGMP is involved, 6 subjects received increasing doses of ascorbic acid in the presence of methylene blue (13 g/minХ10 mol/L), a specific guanylyl cyclase inhibitor. 24 To explore the involvement of potassium channels, 2 other experiments were carried out in PGF 2␣ -preconstricted veins because the nonselective potassium channel inhibitor quinidine is reported to also block ␣-adrenoceptors. 25 First, 6 subjects received ascorbic acid with and without coinfusion of a constant dose of quinidine gluconate (83 g/minХ50 mol/L) on separate study days. This dose of quinidine gluconate had no effect on PGF 2␣ -induced preconstriction in preliminary experiments in 2 subjects (data not shown). Second, 6 subjects received ascorbic acid with coinfusion of a constant dose of glibenclamide (20 g/minХ12 mol/L) during the last 4 doses of ascorbic acid (180 to 6000 g/min). Glibenclamide inhibits ATPdependent potassium channels in the human hand vein in vivo. 21 
In Vitro [Ca

2؉ ] i Measurements in Endothelial Cells
The cytosolic-free calcium concentration ([Ca 2ϩ ] i ) in cultured bovine aortic endothelial cells (BAEC) was quantified by spectrofluorimetry with the Ca 2ϩ -sensitive fluorescent dye fura-2/AM, according to previously published methods. 26, 27 
Data Analysis
Individual dose-response curves to ascorbic acid could not be adequately fitted by an E max model because no maximum effect was established. Therefore, responses to drug treatments were compared with the maximum ascorbic acid dose used (6000 g/min 
Results
Local infusion of ascorbic acid into the dorsal hand veins of healthy volunteers, with or without concomitant local or systemic drugs, had no local or systemic adverse effects and did not influence blood pressure or heart rate (see Table) .
Direct Effects of Ascorbic Acid on Dorsal Hand Vein Distensibility
Infusion of ascorbic acid into phenylephrine-preconstricted hand veins caused vasodilation in a dose-dependent manner ( Figure 1 ). The venodilatory response reached a maximum of 38Ϯ4% at an infusion rate of 6000 g/min. In veins preconstricted with PGF 2␣ , ascorbic acid also caused dose-dependent venodilation (maximum 51Ϯ13%; Figure 1 ). The difference between the two curves in Figure 1 did not reach the level of statistical significance. The venodilation by ascorbic acid reversed rapidly on cessation of the infusion. Venous diameter returned to its phenylephrine-preconstricted or PGF 2␣ -preconstricted baseline 5 to 10 minutes after ascorbic acid infusion was terminated (data not shown).
Involvement of Endothelium-Dependent Factors
Oral pretreatment with ASA (to inhibit cyclooxygenase) or coinfusion of ascorbic acid and L-NMMA (to inhibit NO synthesis) did not significantly affect ascorbic acid-induced venodilation (Figure 2 ). To investigate whether ascorbic acid is able to enhance [Ca 2ϩ ] i in endothelial cells, which could activate the NO synthase and cyclooxygenase, we exposed BAECs to concentrations of ascorbic acid equivalent to the hand vein perfusate that provoked vasodilation in vivo (540, 1600, and 6000 g/min). Assuming local flow in the hand vein of Ϸ3 mL/min, 28 these equate with concentrations of ascorbic acid of Ϸ1, 3, and 10 mmol/L, respectively. The fluorescence ratio as a measure for [Ca 2ϩ ] i in BAECs was minimally affected by ascorbic acid up to 3 mmol/L and decreased significantly with 10 mmol/L (Figure 3, A and B) . However, the subsequent addition of ATP and the detergent digitonin increased the fluorescence ratio significantly less than in cells without prior exposure to ascorbic acid, suggesting that ascorbic acid may chelate [Ca 2ϩ ] i . To test this, the plasma membrane was permeabilized with digitonin, allowing intracellular Fura-2 to saturate with extracellular Ca Figure 4 illustrates the response to ascorbic acid (infusion rate of 6000 g/min) in phenylephrine-preconstricted veins during treatment with methylene blue (to inhibit generation of cGMP). Methylene blue abolished the venodilation (5Ϯ3%; Figure 4 ). In PGF 2␣ -preconstricted veins, coinfusion of the nonselective potassium channel inhibitor quinidine abolished the ascorbic acid-induced venodilation (7Ϯ12%), whereas application of glibenclamide (to inhibit ATP-dependent potassium channels) had no effect (Figure 4) .
Involvement of Endothelium-Independent Mechanisms
Discussion
To the best of our knowledge, this is the first report on direct effects of ascorbic acid on contractile status in human veins. The ascorbic acid-induced venodilation was affected neither by blockade of NO synthesis with L-NMMA nor by inhibition of cyclooxygenase with ASA. It does not increase [Ca 2ϩ ] i in cultured endothelial cells. The venodilation was abolished both by inhibiting guanylate cyclase with methylene blue and by blocking potassium channels with quinidine. Inhibiting ATP-dependent potassium channels with glibenclamide had no effect on venodilation.
Before discussing these findings in detail, we must consider the physiological relevance of the putative tissue concentration of ascorbic acid. The local plasma concentration of ascorbic acid cannot be determined precisely because we did not measure venous flow. Instead, the concentration was estimated to be 3 mmol/L and 10 mmol/L at 1800 g/min and 6000 g/min, respectively. Such high concentrations exceed physiological plasma concentrations of 30 to 80 mol/L by a factor of 40 to 100. 29 Several studies demonstrated that infusion of millimolar concentrations of ascorbic acid improves the endothelium-dependent vasodilation in brachial arteries and speculated scavenging superoxide-mediated improvement of NO-induced responses. 2, 4, [17] [18] [19] However, although ascorbic acid is a superoxide scavenger at low micromolar concentrations (Ͻ100 mol/L), the effective competition with NO for superoxide required a 100-fold higher local concentration (10 mmol/L) in rabbit aorta. 30 In contrast, superoxide dismutase and EUK-8 (a nonprotein catalytic antioxidant) scavenge free radicals and compete with NO for superoxide at the same concentration (0.2 and 1 mol/L, respectively). 30 Thus, antioxidative properties of ascorbic acid may not be the only mechanism involved, because low micromolar concentrations of ascorbic acid did not dilate in the appropriate concentration range for free radical scavenging.
Involvement of Endothelium-Dependent Factors in Ascorbic Acid-Induced Dilation
In endothelial cellular signaling, increase in [Ca 2ϩ ] i 31 results in generation and release of NO and prostacyclin, leading to vasodilation. 32 In our endothelial cell model, millimolar concentrations of ascorbic acid had no effect on basal [ 34 Alternative mechanisms of action of ascorbic acid relate to its reducing and radical scavenger properties. As a reducing agent, ascorbic acid may alter the redox state of soluble guanylyl cyclase in vascular smooth muscle cells, which is sensitized to NO, thus mediating relaxation. 35 Superoxide reduces relaxation by partially inactivating endothelial NO. Because ascorbic acid in millimolar concentration scavenges superoxide radicals, it increases the availability of NO. 30 Ascorbic acid has been shown to stimulate NO production after 24 hours of incubation with low micromolar concentrations (100 to 200 mol/L). 36 Because sodium-dependent, carrier-mediated active transport into endothelial cells exists, 37, 38 extended incubation may increase the intracellular concentration of ascorbic acid. Under physiological conditions, this concentration is in the range of 1 to 2.5 mmol/L, that is, Ϸ20 times higher than in plasma. 39 In our study, blockade of NO synthase with L-NMMA had no effect on ascorbic acid-induced venodilation. However, nonenzymatic NO production has been demonstrated in humans. 40 We cannot exclude that under physiological conditions, nonenzymatic NO production from nitrite occurs, but we assume that the role of nonenzymatic NO production should be negligible because of the nonphysiological acidic conditions (threshholdϭpH 6) required for this reaction. 41 Such pH conditions were unlikely to be present in our study (see Methods).
Although ascorbic acid also increases prostacyclin production in endothelial cells, 42 inhibition of cyclooxygenase with ASA did not modulated ascorbic acid-induced venodilation. Thus, NO and vasodilatory cyclooxygenase products are not involved. It is possible, however, that the time of exposure to ascorbic acid was too short, so that no effect on NO synthase or cyclooxygenase could occur. On the other hand, these . Endothelium-independent effects of vitamin C. A, In hand veins preconstricted with phenylephrine, ascorbic acid (6000 g/min) was infused alone (control 1; nϭ9) and in combination with methylene blue (13 g/min; nϭ6) . B, In hand veins preconstricted with PGF 2␣ , ascorbic acid (6000 g/min) was infused alone (control 2; nϭ6) and in combination with glibenclamide (20 g/min; nϭ6) or quinidine gluconate (83 g/min; nϭ6). Asterisks denote significant differences vs respective control (PϽ0.001). Note that control 1 is the same as in Figure 2 .
results may indicate a possible endothelium-independent effect of ascorbic acid in the hand vein.
Involvement of Endothelium-Independent Factors in Ascorbic Acid-Induced Dilation
Ascorbic acid causes hyperpolarization in various cells, 43, 44 which can originate from activation of potassium channels or of membrane Na ϩ -K ϩ ATPase. 45 In our study, quinidine, a nonselective potassium channel inhibitor, completely blocked the ascorbic acid-induced venodilation, suggesting possible involvement of potassium channels. Activation of potassium channels has been described as a key mechanism of smooth muscle relaxation caused by NO and prostacyclin. Hence, ascorbic acid-induced activation of potassium channels in vascular smooth muscle appears to be independent of endothelial vasoactive mediators.
Quinidine is a nonselective inhibitor of potassium channels in the human vasculature. 46, 47 In addition to its ability to block potassium channels, this drug exerts also antiadrenergic, 25 anticholinergic, and calcium channel-blocking and sodium channel-blocking properties. 48 Interaction with ␣ -adrenoceptors can be excluded because we used PGF 2␣ as venoconstrictor. Because neither nifedipine nor lodocain dilate human hand veins in vivo, 21 L-type calcium channels or sodium channels are unlikely to contribute. On the other hand, application of high concentrations of atropine significantly dilate phenylephrine-preconstricted human veins (M. Grossmann and D. Dobrev, 1999, unpublished observations), implying involvement of muscarinic receptors. In dosefinding studies for quinidine, we initially applied 500 g/min, as used by Smits et al, 47 and found substantial venodilation in which all the multiple effects of quinidine, including anticholinergic action, could be involved. However, at the dose eventually selected, quinidine had no dilatory effect during 70 minutes of infusion (data not shown). Therefore, quinidineinduced block of ascorbic acid-induced venodilation is likely to be due to nonselective inhibition of potassium channels.
Which potassium channels might be involved? Quinidine modulates voltage-gated (K V ), calcium-activated (K Ca ), inward rectifier (K IR ), and ATP-dependent (K ATP ) potassium channels. 48 In an attempt to define the type of potassium channels involved, we blocked K ATP channels with glibenclamide 21 and found no effect, excluding involvement of K ATP channels. Unfortunately, additional experiments with charybdotoxin (selective blocker of K Ca ) or 4-aminopyridine (selective blocker of K V ) could not been conducted because these compounds cannot be used in humans. Therefore, the type of potassium channel involved in the ascorbic acid-induced venodilation remains elusive.
Activity of potassium channels in smooth muscle cells may be modulated by cGMP. Our finding that methylene blue, an inhibitor of soluble guanylate cyclase, abolished the venodilation indicates a possible involvement of cGMP generation. NO is the major endogenous activator of the guanylyl cyclase in smooth muscle cells. 45 Because in our study an NOmediated action of ascorbic acid is unlikely, a direct action of ascorbic acid on cGMP generation may be postulated. As previously described, the reducing agent ascorbic acid may alter the redox state of the soluble guanylyl cyclase and activate the cGMP production. 35, 49 Indeed, ascorbic acid relaxes rat and guinea pig thoracic aorta in vitro in a concentration-dependent manner, and this effect is also inhibited by methylene blue. 50 
Limitations of the Study
First, the study has been conducted in healthy subjects as a prelude to experiments in patients with coronary artery disease. However, these effects may be missing in this patient population. Second, neither intracellular generation of cGMP nor activation of potassium channels were measured because examination of the in vivo effects of ascorbic acid on production of cGMP and on activation of potassium channels in vascular smooth muscle cells is feasible only in biopsies. Third, we did not investigate the effects of other antioxidants such as vitamin E and ␤-carotene. Thus, the potential beneficial effects of ascorbic acid are not necessarily representative for other antioxidants.
Conclusions
Local infusion of ascorbic acid into preconstricted dorsal hand veins of healthy subjects causes dose-dependent vasodilation that can neither be attributed to stimulation of NO synthase or cyclooxygenase activities nor to increased endothelial [Ca 2ϩ ] i . Instead, cGMP formation and potassium channel activation appear to be involved in the response. As a possible explanation for the observed effects, we suggest that ascorbic acid modulates the redox state of soluble guanylyl cyclase, thereby activating cGMP-dependent potassium channels that hyperpolarize the smooth muscle cell membrane and thus induce vasodilation. Thus, further detailed investigations of the direct effects of ascorbic acid on human venous smooth muscle cells are needed because in a clinical setting, venodilatory effects of ascorbic acid are relevant with respect to the wide use of organic nitrates.
